Acta pharmacologica Sinica
May 19, 2026
Jun-Nan Xu, Jing-Ting Li, Ru-Xia Xu et al.
Diminished drive is one of the core symptoms of major depressive disorder (MDD) diagnosis, yet its underlying neural mechanisms remain elusive, primarily due to a lack of appropriate animal models. We developed a novel Multilevel Exploration Test (MET) apparatus to evaluate exploratory behavior, which is captured as a dynamic, stage-dependent process involving "search", "attend/investigate",...
Lecture Notes in Education Psychology and Public Media
May 18, 2026
Fanyue Kong
Mindfulness meditation is increasingly recognized as an effective psychological intervention for emotional regulation. Millions of people worldwide suffer from depression and anxiety, which are the most common mental health conditions amd present significant public health issues. This study examines the effects of short-term mindfulness meditation on depression and anxiety in adults. A...
Journal of Affective Disorders
May 16, 2026
David S. Mathai, Madeleine Cluck, Amna M. Aslam et al.
1 citation
Background: Off-label use of intravenous ketamine (IVK) for depression is a widespread practice with limited regulation in the United States. There is an urgent need for current, evidence-informed treatment guidelines to facilitate patient safety, clinical decision-making, and care quality in real-world contexts. Methods: The American Society of Ketamine Physicians, Psychotherapists and...
Asian Journal of Psychiatry
May 16, 2026
Sonia Shenoy, Vijetha Shenoy Belle, Ravindra Neelakanthappa Munoli et al.
1 citation
Background: Oral ketamine is a novel treatment for management of depression. However, evidence related to its effectiveness and safety is unavailable. This systematic review aimed to assess the short-term efficacy and safety of oral ketamine compared to placebo or other modes of ketamine in randomized controlled trials (RCT) in unipolar depression, bipolar depression, and treatment-resistant...
JAMA Network Open
May 15, 2026
Hampus Yngwe, Pontus Plavén-sigray, Carl Johan Ekman et al.
1 citation
Importance: Psilocybin has been proposed as a rapid-acting antidepressant (onset 6 weeks), but evidence from randomized clinical trials remains limited, particularly in the broader major depressive disorder (MDD) population. Objective: To assess short-term and long-term antidepressant effects of psilocybin therapy in patients with MDD. Design, Setting, and Participants: This double-blind,...
Journal of Medical Internet Research
May 14, 2026
Giovanni Ramos, Amanda K Montoya, Adrian Aguilera et al.
Background: Racially and ethnically minoritized individuals (REMs) who experience discrimination are at risk of developing stress, anxiety, and depression, and digital mental health interventions (DMHIs) can make evidence-based treatments such as mindfulness available to these groups. However, REMs are significantly underrepresented in the overall DMHI and mindfulness-based DMHI literature,...
Behavioral Sciences
May 14, 2026
Fabiola Raffone, Carlo Ignazio Cattaneo, Enrico Pessina et al.
Trauma-related autobiographical memories can manifest as involuntary, vivid, emotionally charged intrusions that perpetuate avoidance, negative emotions, and functional impairment. While these memories are central to post-traumatic stress disorder (PTSD), they also occur across diagnoses and are often reported in depressive disorders, including treatment-resistant depression (TRD). Although...
Journal of Affective Disorders
May 14, 2026
Joshua Curtiss, Laya Dasari, Julianne Origlio et al.
Major Depressive Disorder (MDD) affects millions globally, with approximately 30% of patients experiencing treatment-resistant depression (TRD). While ketamine has emerged as a rapid-acting intervention, response rates remain variable, underscoring the need to refine precision medicine approaches for ketamine treatment. Network theories of mental health disorders have been promoted as framework...
Fortschritte der Neurologie · Psychiatrie
May 13, 2026
Cornelius Schüle, Anna Sobieraj, Helena Rogg
1 citation
Abstract: Esketamine is an NMDA receptor antagonist and was approved as a nasal spray in March 2019, initially in the USA and then in December 2019 in Europe, as an adjunct to antidepressant pharmacotherapy for the treatment of treatment-resistant major depression or for rapid symptom reduction in psychiatric emergency situations in patients with major depression. In addition, esketamine nasal...
Suchttherapie
May 12, 2026
Louise Penzenstadler, Tatiana Aboulafia Brakha, Daniele Zullino
Zusammenfassung Substanzkonsumstörungen (SUD) sind chronische Erkrankungen mit hohen Rückfallraten und begrenzter Wirksamkeit etablierter Behandlungen. Vor diesem Hintergrund rückt die psychedelisch-assistierte Psychotherapie (PAP) mit Psilocybin und LSD zunehmend in den Fokus; die Literatur berichtet Hinweise auf mögliche Effekte insbesondere bei AUD und affektiven Symptomen. Ziel der Studie:...
Journal of Pre-Clinical and Clinical Research
May 12, 2026
Bartłomiej Kosiarski, A. Skrzypek, Patrycja Markowicz et al.
Rapid-acting interventions in treatment-resistant depression – a comparative review of
Frontiers in Psychology
May 12, 2026
Xi Zhang, Hongyan Wang, Xiaohui Wang et al.
Objective To evaluate the efficacy of MBI on depression among family caregivers of dementia patients, and to analyze the impact of intervention duration, follow-up period, and intervention methods on treatment outcomes. Methods Search Embase, The Cochrane Library, CINAHL, PubMed, SinoMed, CNKI, Wanfang, and VIP databases for randomized controlled trials on MBI for depression in family...
Translational Psychiatry
May 12, 2026
Linda Bryant, Laith Alexander, Sergio Mena et al.
Ketamine has demonstrated rapid antidepressant efficacy in treatment-resistant depression (TRD), but clinical decision-making is challenging due to variability in individual response. Current trial-and-error prescribing practices may expose patients to ineffective treatment and avoidable adverse effects, underscoring the need for reliable predictive tools to optimize treatment selection and...
Psychiatry Research
May 12, 2026
Isis Lunsky, Gilmar Gutierrez, Xena Wang et al.
Postpartum Depression (PPD) is a common condition with serious consequences for both mother and baby if left untreated. Currently, few effective strategies exist for prevention of PPD. Ketamine and Esketamine are rapid acting and potent antidepressants, and emerging evidence is showing promising results for PPD. This review searched the MEDLINE, CINAHL, PsycINFO, EMBASE, and Cochrane databases,...
Premier Journal of Neuroscience
May 11, 2026
Khadija Kamene
Background: Treatment-resistant depression (TRD) affects a significant proportion of individuals with major depressive disorder and remains difficult to manage with conventional treatments. Psychedelic-assisted therapies and neuromodulation have emerged as innovative interventions targeting neurobiological mechanisms beyond traditional antidepressant approaches. Objectives: This scoping review...
Research Square
May 11, 2026
Chloë K Walters, Sarentha Chetty, Thankhoe A Rants’o et al.
preprint
Abstract Background: Conventional pharmacotherapy for treatment-resistant depression (TRD) has been found to provide limited benefit in a subset of patients. Psilocybin‑assisted therapy has emerged as a promising modality due to its rapid‑acting antidepressant effects and favourable tolerability profile shown in early trials. Despite growing research interest in psilocybin‑assisted therapy the...
Archives of Suicide Research
May 9, 2026
Gregory Carter, Maree Hackett, Stevan Nikolin et al.
Ketamine has disputed effects on suicidal ideation scores in depressed populations. This study assessed effectiveness of ketamine in adults with treatment resistant depression, examining a secondary outcome of suicidal ideation. Phase III, double-blind, randomized, active-controlled, multicenter trial. Participants were randomized to twice-weekly subcutaneous racemic ketamine or midazolam for 4...
International Journal of Molecular Sciences
May 9, 2026
Marta Jóźwiak-Bębenista, Anna Stasiak, Monika Sienkiewicz et al.
Aging is associated with chronic, low-grade inflammation ("inflammaging"), which contributes to neuropsychiatric and neurodegenerative disorders such as depression, Alzheimer's disease, and Parkinson's disease. Conventional pharmacotherapies often provide limited benefit in older adults and are further complicated by polypharmacy and drug-drug interactions. Psilocybin, a serotonergic...
SLEEPJ
May 8, 2026
Heba A Afaneh, David A Kalmbach, Philip Cheng et al.
Abstract Introduction Insomnia affects half of pregnant women and increases risk for depression. Identifying effective treatments for co-occurring insomnia and depression during pregnancy remains a critical priority. Cognitive-behavioral therapy for insomnia (CBTI) improves sleep quality but has limited impact on depression—an effect attributed to persistent cognitive arousal (worry and...
Psychological Medicine
May 8, 2026
Lou-Anne Chavigny, Véronique Desbeaumes Jodoin, Nicolas Garel et al.
Intravenous (IV) low-dose ketamine has emerged as a promising treatment for patients with treatment-resistant depression (TRD). However, its impact on cognitive functioning remains unclear. This systematic review examines the cognitive and executive effects of IV ketamine in TRD, focusing on their relationship to depressive and suicidal outcomes. A systematic search of Cochrane, MEDLINE,...